Fidelis Capital Partners’s ResMed RMD Stock Holding History

Fidelis Capital Partners’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$292K	Buy	1,299 +29	+2%	+$7.23K	0.02%	408
2025 Q4	$306K	Sell	1,270 -4	-0.3%	-$1.02K	0.02%	390
2025 Q3	$349K	Buy	1,274 +96	+8%	+$26.2K	0.03%	365
2025 Q2	$330K	Buy	1,178 +115	+11%	+$27.4K	0.03%	329
2025 Q1	$251K	Sell	1,063 -47	-4%	-$11K	0.03%	360
2024 Q4	$267K	Buy	1,110 +11	+1%	+$2.65K	0.03%	357
2024 Q3	$261K	Buy	1,099 +12	+1%	+$2.68K	0.03%	339
2024 Q2	$229K	Buy	1,087 +6	+0.6%	+$1.22K	0.03%	330
2024 Q1	$214K	Buy	+1,081	New	+$198K	0.03%	346

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelis Capital Partners's RMD Position: Q1 2026 in Review

Fidelis Capital Partners increased its ResMed (RMD) stake by 2.3% in Q1 2026, buying an estimated $7.23K and bringing the position to 1,299 shares worth $292K. The position accounts for 0.02% of the portfolio, ranked #408.

Fidelis Capital Partners first reported a position in RMD in Q1 2024 and has held it in 9 quarters since. The position peaked at $349K in Q3 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Fidelis Capital Partners held 1,299 shares of ResMed worth $292K as of Q1 2026.
Fidelis Capital Partners bought 29 ResMed shares in Q1 2026, an estimated $7.23K.
ResMed made up 0.02% of Fidelis Capital Partners's portfolio in Q1 2026, its #408 holding.
Fidelis Capital Partners first reported a position in ResMed in Q1 2024 and has held it in 9 quarters since.
Fidelis Capital Partners's ResMed position peaked at $349K in Q3 2025.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Fidelis Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.